Comparison Between the Effect of Omeprazole and Rabeprazole on the Antiplatelet Action of Clopidogrel

10.1161/CIRCULATIONAHA.108.191087

10.1111/j.1538-7836.2007.02775.x

10.1182/blood-2006-04-013052

4. Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13: 27-36.

10.1016/j.jacc.2007.06.064

10.1177/0091270008315310

10.1016/j.ahj.2008.11.004

10.1001/jama.2009.261

9. FDA Approved Drug Products. Product on application of rabeprazole sodium. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20973S013lbl.pdf (accessed 18 May, 2009).

10. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827.

10.1161/01.CIR.0000099507.32936.C0

12. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, et al. Absence of interaction between atorvastatin or other statins and clopidogrel. Arch Intern Med 2004; 164: 2051-2057.

10.1016/j.jacc.2007.04.041

10.1253/circj.CJ-08-1120

15. Erlinge D, Varenhorst C, Braun OÖ, James S, Winters KJ, Jakubowski JA, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added Ex Vivo. J Am Coll Cardiol 2008; 52: 1968-1977.

10.1016/j.jacc.2006.06.065

17. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 2007; 115: 1-8.

18. Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients. Circ J 2008; 72: 35-39.

19. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, et al. Clopidogrel resistance in Japanese patients scheduled for Percutaneous Coronary Intervention. Circ J 2009; 73: 336-342.

10.1016/j.jacc.2007.01.094

10.1016/j.jacc.2006.06.049

22. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-287.

23. Patel P, Gonzales R, Dokainish H, Lakkis N. Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy. J Am Coll Cardiol 2006; 47: 464-465.

24. Giustia B, Goria AM, Marcuccia R, Saracinia C, Sestinia I, Panicciaa R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 +12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenetics Genom 2007; 17: 1057-1064.

25. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.

10.1253/circj.72.1165

10.2133/dmpk.21.286

10.1097/00008571-200204000-00006

29. Yamada S, Onda M, Kato S, Matsuda N, Matsuhisa T, Yamada N, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 2001; 36: 669-672.